Cargando…

Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST)

Palliative imatinib treatment has dramatically improved survival in patients with malignant gastrointestinal stromal tumours, particularly in patients with tumours harbouring activating KIT mutations. To evaluate the effectiveness of adjuvant imatinib after radical surgery, a consecutive series of p...

Descripción completa

Detalles Bibliográficos
Autores principales: Nilsson, B, Sjölund, K, Kindblom, L-G, Meis-Kindblom, J M, Bümming, P, Nilsson, O, Andersson, J, Ahlman, H
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2359924/
https://www.ncbi.nlm.nih.gov/pubmed/17533389
http://dx.doi.org/10.1038/sj.bjc.6603797
_version_ 1782152921158254592
author Nilsson, B
Sjölund, K
Kindblom, L-G
Meis-Kindblom, J M
Bümming, P
Nilsson, O
Andersson, J
Ahlman, H
author_facet Nilsson, B
Sjölund, K
Kindblom, L-G
Meis-Kindblom, J M
Bümming, P
Nilsson, O
Andersson, J
Ahlman, H
author_sort Nilsson, B
collection PubMed
description Palliative imatinib treatment has dramatically improved survival in patients with malignant gastrointestinal stromal tumours, particularly in patients with tumours harbouring activating KIT mutations. To evaluate the effectiveness of adjuvant imatinib after radical surgery, a consecutive series of patients with high-risk tumours (n=23) was compared with historic controls (n=48) who were treated with surgery alone. The mean follow-up period was over 3 years in both groups. Only 1 out of 23 patients (4%) in the adjuvant treatment group developed recurrent disease compared to 32 out of 48 patients (67%) in the control group. This preliminary study indicates that 1 year of adjuvant treatment with imatinib dramatically improves recurrence-free survival. Confirmation of these findings awaits the results of ongoing randomised studies.
format Text
id pubmed-2359924
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23599242009-09-10 Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST) Nilsson, B Sjölund, K Kindblom, L-G Meis-Kindblom, J M Bümming, P Nilsson, O Andersson, J Ahlman, H Br J Cancer Clinical Study Palliative imatinib treatment has dramatically improved survival in patients with malignant gastrointestinal stromal tumours, particularly in patients with tumours harbouring activating KIT mutations. To evaluate the effectiveness of adjuvant imatinib after radical surgery, a consecutive series of patients with high-risk tumours (n=23) was compared with historic controls (n=48) who were treated with surgery alone. The mean follow-up period was over 3 years in both groups. Only 1 out of 23 patients (4%) in the adjuvant treatment group developed recurrent disease compared to 32 out of 48 patients (67%) in the control group. This preliminary study indicates that 1 year of adjuvant treatment with imatinib dramatically improves recurrence-free survival. Confirmation of these findings awaits the results of ongoing randomised studies. Nature Publishing Group 2007-06-04 2007-05-29 /pmc/articles/PMC2359924/ /pubmed/17533389 http://dx.doi.org/10.1038/sj.bjc.6603797 Text en Copyright © 2007 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Clinical Study
Nilsson, B
Sjölund, K
Kindblom, L-G
Meis-Kindblom, J M
Bümming, P
Nilsson, O
Andersson, J
Ahlman, H
Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST)
title Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST)
title_full Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST)
title_fullStr Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST)
title_full_unstemmed Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST)
title_short Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST)
title_sort adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (gist)
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2359924/
https://www.ncbi.nlm.nih.gov/pubmed/17533389
http://dx.doi.org/10.1038/sj.bjc.6603797
work_keys_str_mv AT nilssonb adjuvantimatinibtreatmentimprovesrecurrencefreesurvivalinpatientswithhighriskgastrointestinalstromaltumoursgist
AT sjolundk adjuvantimatinibtreatmentimprovesrecurrencefreesurvivalinpatientswithhighriskgastrointestinalstromaltumoursgist
AT kindblomlg adjuvantimatinibtreatmentimprovesrecurrencefreesurvivalinpatientswithhighriskgastrointestinalstromaltumoursgist
AT meiskindblomjm adjuvantimatinibtreatmentimprovesrecurrencefreesurvivalinpatientswithhighriskgastrointestinalstromaltumoursgist
AT bummingp adjuvantimatinibtreatmentimprovesrecurrencefreesurvivalinpatientswithhighriskgastrointestinalstromaltumoursgist
AT nilssono adjuvantimatinibtreatmentimprovesrecurrencefreesurvivalinpatientswithhighriskgastrointestinalstromaltumoursgist
AT anderssonj adjuvantimatinibtreatmentimprovesrecurrencefreesurvivalinpatientswithhighriskgastrointestinalstromaltumoursgist
AT ahlmanh adjuvantimatinibtreatmentimprovesrecurrencefreesurvivalinpatientswithhighriskgastrointestinalstromaltumoursgist